{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:02Z","timestamp":1786982762353,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["2014s029"],"award-info":[{"award-number":["2014s029"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40264-023-01283-7","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T16:31:51Z","timestamp":1681317111000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug\u2013Drug Interactions and the Risk of Emergency Hospitalizations: A Nationwide Population-Based Study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-4866","authenticated-orcid":false,"given":"Louis","family":"L\u00e9tinier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jarne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"1283_CR1","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743\u2013800."},{"key":"1283_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2146\/ajhp130767","volume":"71","author":"GT Schumock","year":"2014","unstructured":"Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2014. Am J Health Syst Pharm. 2014;71:482\u201399.","journal-title":"Am J Health Syst Pharm"},{"key":"1283_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00228-017-2288-1","volume":"73","author":"N Abolhassani","year":"2017","unstructured":"Abolhassani N, Castioni J, Marques-Vidal P, Vollenweider P, Waeber G. Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study. Eur J Clin Pharmacol. 2017;73:1187\u201394.","journal-title":"Eur J Clin Pharmacol"},{"key":"1283_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194892","volume":"13","author":"JW Wastesson","year":"2018","unstructured":"Wastesson JW, Minguez AC, Fastbom J, Maioli S, Johnell K. The composition of polypharmacy: a register-based study of Swedes aged 75 years and older. PLoS ONE. 2018;13: e0194892.","journal-title":"PLoS ONE"},{"key":"1283_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;13:74.","journal-title":"BMC Med"},{"key":"1283_CR6","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999\u20132012. JAMA. 2015;314:1818\u201330.","journal-title":"JAMA"},{"key":"1283_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/jamainternmed.2015.8581","volume":"176","author":"DM Qato","year":"2016","unstructured":"Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176:473\u201382.","journal-title":"JAMA Intern Med"},{"key":"1283_CR8","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.3390\/jcm9113728","volume":"9","author":"J Guillot","year":"2020","unstructured":"Guillot J, Maumus-Robert S, Marceron A, Noize P, Pariente A, Bezin J. The burden of potentially inappropriate medications in chronic polypharmacy. J Clin Med. 2020;9:3728.","journal-title":"J Clin Med"},{"key":"1283_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fphar.2019.00265","volume":"10","author":"L L\u00e9tinier","year":"2019","unstructured":"L\u00e9tinier L, Cossin S, Mansiaux Y, et al. Risk of drug-drug interactions in out-hospital drug dispensings in France: results from the DRUG-Drug Interaction Prevalence Study. Front Pharmacol. 2019;10:265.","journal-title":"Front Pharmacol"},{"key":"1283_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11096-010-9365-1","volume":"32","author":"A Chatsisvili","year":"2010","unstructured":"Chatsisvili A, Sapounidis I, Pavlidou G,\u00a0 et al. Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci. 2010;32:187\u201393.","journal-title":"Pharm World Sci"},{"key":"1283_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3851\/IMP1540","volume":"15","author":"C Marzolini","year":"2010","unstructured":"Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther (Lond). 2010;15:413\u201323.","journal-title":"Antivir Ther (Lond)."},{"key":"1283_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/bjc.2013.48","volume":"108","author":"RWF van Leeuwen","year":"2013","unstructured":"van Leeuwen RWF, Brundel DHS, Neef C, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108:1071\u20138.","journal-title":"Br J Cancer"},{"key":"1283_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsps.2019.11.009","volume":"28","author":"MB Nusair","year":"2020","unstructured":"Nusair MB, Al-Azzam SI, Arabyat RM, Amawi HA, Alzoubi KH, Rabah AA. The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan. Saudi Pharm J. 2020;28:155\u201360.","journal-title":"Saudi Pharm J."},{"key":"1283_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1007\/s11096-020-01068-3","volume":"42","author":"W Ren","year":"2020","unstructured":"Ren W, Liu Y, Zhang J, et al. Prevalence of potential drug-drug interactions in outpatients of a general hospital in China: a retrospective investigation. Int J Clin Pharm. 2020;42:1190\u20136.","journal-title":"Int J Clin Pharm"},{"key":"1283_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00002512-199812060-00006","volume":"12","author":"RM Seymour","year":"1998","unstructured":"Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12:485\u201394.","journal-title":"Drugs Aging"},{"key":"1283_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","volume":"16","author":"ML Becker","year":"2007","unstructured":"Becker ML, Kallewaard M, Caspers PWJ, Visser LE, Leufkens HGM, Stricker BHC. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641\u201351.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1283_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/pds.3592","volume":"23","author":"S Dechanont","year":"2014","unstructured":"Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions\/visits associated with drug\u2013drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489\u201397.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1283_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cpt.1376","volume":"106","author":"K Bykov","year":"2019","unstructured":"Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Gagne JJ. A case-crossover-based screening approach to identifying clinically relevant drug-drug interactions in electronic healthcare data. Clin Pharmacol Ther. 2019;106:238\u201344.","journal-title":"Clin Pharmacol Ther"},{"key":"1283_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40266-020-00767-w","volume":"37","author":"A De Vincentis","year":"2020","unstructured":"De Vincentis A, Gallo P, Finamore P, et al. Potentially inappropriate medications, drug-drug interactions, and anticholinergic burden in elderly hospitalized patients: does an association exist with post-discharge health outcomes? Drugs Aging. 2020;37:585\u201393.","journal-title":"Drugs Aging"},{"key":"1283_CR20","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3389\/fphar.2020.608068","volume":"11","author":"H Hochheiser","year":"2021","unstructured":"Hochheiser H, Jing X, Garcia EA, et al. A minimal information model for potential drug-drug interactions. Front Pharmacol. 2021;11:2477.","journal-title":"Front Pharmacol"},{"key":"1283_CR21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/bcp.14510","volume":"87","author":"J Bezin","year":"2021","unstructured":"Bezin J, Noize P, Mansiaux Y, Jarne A, Pariente A. Antidopaminergic antiemetics and trauma-related hospitalization: a population-based self-controlled case series study. Br J Clin Pharmacol. 2021;87:1303\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1283_CR22","unstructured":"Th\u00e9saurus des interactions m\u00e9dicamenteuses. ANSM. 2021. Available from: https:\/\/ansm.sante.fr\/documents\/reference\/thesaurus-des-interactions-medicamenteuses-1. [Accessed 13 Dec 2022]."},{"key":"1283_CR23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1283_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0140-6736(95)90471-9","volume":"345","author":"P Farrington","year":"1995","unstructured":"Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria\/tetanus\/pertussis and measles\/mumps\/rubella vaccines. Lancet. 1995;345:567\u20139.","journal-title":"Lancet"},{"key":"1283_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4515","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354: i4515.","journal-title":"BMJ"},{"key":"1283_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2105\/AJPH.88.1.15","volume":"88","author":"B Rockhill","year":"1998","unstructured":"Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health. 1998;88:15\u20139.","journal-title":"Am J Public Health"},{"key":"1283_CR27","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/sim.2302","volume":"25","author":"HJ Whitaker","year":"2006","unstructured":"Whitaker HJ, Paddy Farrington C, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25:1768\u201397.","journal-title":"Stat Med"},{"key":"1283_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.ajem.2019.01.049","volume":"37","author":"T Jawaro","year":"2019","unstructured":"Jawaro T, Bridgeman PJ, Mele J, Wei G. Descriptive study of drug-drug interactions attributed to prescriptions written upon discharge from the emergency department. Am J Emerg Med. 2019;37:924\u20137.","journal-title":"Am J Emerg Med"},{"key":"1283_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00228-003-0684-1","volume":"59","author":"L Gu\u00e9don-Moreau","year":"2003","unstructured":"Gu\u00e9don-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol. 2003;59:689\u201395.","journal-title":"Eur J Clin Pharmacol"},{"key":"1283_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034560","volume":"10","author":"B Danielsson","year":"2020","unstructured":"Danielsson B, Collin J, Nyman A, et al. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study. BMJ Open. 2020;10: e034560.","journal-title":"BMJ Open"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01283-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01283-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01283-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:18:17Z","timestamp":1683353897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01283-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01283-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"26 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study is part of the Drugs Systematized Assessment in real-liFe Environment (DRUGS-SAFE) research program that is funded in part by the French Medicines Agency (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9, ANSM); grant number 2014s029. This program aims at creating an integrated system for the concomitant monitoring of drug use and safety in France. The potential impact of drugs, the frailty of populations, and the seriousness of risks drive the research program. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. This publication represents the views of the authors and does not necessarily represent the opinion of the French Medicines Agency.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare research grants from the French Medicines Agency (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9, ANSM).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received the consent of The National Institute for Health Data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"Publicly sharing EGB data is forbidden by law according to the French national data protection agency (Commission Nationale de l\u2019Informatique et des LIbert\u00e9s, CNIL); regulatory decisions AT\/CPZ\/SVT\/JB\/DP\/CR05222O of 14 June, 2005 and DP\/CR071761 of 28 August, 2007. To request data access, please contact The National Institute for Health Data (Institut National des Donn\u00e9es de Sant\u00e9, INDS; website:\n                      \n                      ).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LL, JB, and AP contributed to the conception and design; AJ contributed to data acquisition; LL and AJ contributed to data analysis; LL, JB, AJ, and AP contributed to data interpretation; LL contributed to drafting of the article; JB, AJ, and AP critically revised the article for important intellectual content. All authors read and approved the final version of the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}